112,700 Shares in Vir Biotechnology, Inc. $VIR Acquired by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio acquired a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 112,700 shares of the company’s stock, valued at approximately $1,010,000.

Other hedge funds have also recently added to or reduced their stakes in the company. GSK plc bought a new stake in shares of Vir Biotechnology during the fourth quarter worth $51,562,000. State Street Corp lifted its stake in shares of Vir Biotechnology by 18.9% in the 4th quarter. State Street Corp now owns 6,229,555 shares of the company’s stock valued at $37,564,000 after acquiring an additional 988,262 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Vir Biotechnology by 1.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,579,678 shares of the company’s stock valued at $23,107,000 after acquiring an additional 43,401 shares in the last quarter. Orbimed Advisors LLC boosted its holdings in shares of Vir Biotechnology by 5.9% during the 2nd quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company’s stock valued at $11,999,000 after acquiring an additional 132,466 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Vir Biotechnology by 3.6% during the 4th quarter. Geode Capital Management LLC now owns 2,328,207 shares of the company’s stock worth $14,041,000 after acquiring an additional 81,985 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Analyst Upgrades and Downgrades

VIR has been the subject of a number of recent research reports. Morgan Stanley upped their target price on Vir Biotechnology from $23.00 to $27.00 and gave the stock an “overweight” rating in a report on Thursday, June 11th. Wall Street Zen cut Vir Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Wednesday, July 8th. Finally, Leerink Partners raised their price objective on shares of Vir Biotechnology from $20.00 to $21.00 and gave the company an “outperform” rating in a report on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Vir Biotechnology presently has an average rating of “Moderate Buy” and a consensus target price of $20.88.

Vir Biotechnology Stock Up 2.8%

Shares of Vir Biotechnology stock opened at $8.90 on Tuesday. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -2.84 and a beta of 1.66. Vir Biotechnology, Inc. has a twelve month low of $4.16 and a twelve month high of $11.66. The company’s fifty day moving average is $9.33 and its 200 day moving average is $8.99.

Vir Biotechnology (NASDAQ:VIR) last announced its earnings results on Wednesday, May 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.84). Vir Biotechnology had a negative return on equity of 53.31% and a negative net margin of 638.88%.The company had revenue of ($0.03) million for the quarter, compared to the consensus estimate of $55.49 million. During the same period in the prior year, the business earned ($0.88) earnings per share. As a group, equities analysts anticipate that Vir Biotechnology, Inc. will post -1.81 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Vir Biotechnology news, Director Janet Napolitano sold 3,200 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.45, for a total transaction of $30,240.00. Following the sale, the director owned 21,216 shares of the company’s stock, valued at approximately $200,491.20. This represents a 13.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.90% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.